Table 1.
Variables | (n = 36) |
---|---|
Age | 83.64 (8.11)b |
Sex | |
Female | 17 (47.2)a |
Male | 19 (52.8) |
Neurologic diseases | 10 (27.8)b |
Cardiovascular diseases | 30 (83.3)b |
Respiratory diseases | 12 (33.3)b |
Other comorbidities | 31 (86.1)b |
Days with symptoms | 5.72 (1.54)b |
Functional status (Barthel Index) | |
Independent | 6 (16.7)a |
Minimally dependent | 12 (33.3) |
Partially dependent | 7 (19.4) |
Very dependent | 8 (22.2) |
Total dependent | 3 (8.3) |
Geriatric Depression Scale (GDS) | |
No cognitive decline | 18 (50)a |
Very mild cognitive decline | 8 (22.2) |
Mild cognitive decline | 5 (13.9) |
Moderate cognitive decline | – |
Moderately severe cognitive decline | 2 (5.6) |
Severe cognitive decline | 3 (8.3) |
Very severe cognitive decline | – |
Pharmacological treatment | |
Corticosteroids (dexamethasone) | 36 (100)a |
Remdesivir | 2 (5.6) |
Tocelizumab | 2 (5.6) |
Basal SpO2 | 94.28 (2.85)b |
Basal SaFi | 255.42 (117.75)b |
Mild | 18 (50)a |
Moderate | 5 (13.9) |
Severe | 13 (36.1) |
Basal PaFi | 251.39 (128.19)b |
Mild | 25 (69.4)a |
Moderate | 4 (11.1) |
Severe | 7 (19.4) |
CURB-65 Score | |
1 points | – |
2 points | 10 (27.8)a |
3 points | 17 (47.2) |
4 points | 9 (25) |
CT lung involvement (%) | |
< 5% | – |
5–25% | 1 (2.8)a |
26–50% | 7 (19.4) |
51–75% | 18 (50) |
> 75% | 10 (27.8) |
Final status | |
Alive | 23 (63.9)a |
Death due to COVID-19 | 8 (22.2) |
Death due to other causes | 5 (13.9) |
CT Computed Tomography; CURB-65 validated clinical prediction score for predicting mortality in community-acquired pneumonia and infection of any site including measurement of: Confusion of new onset, Blood Urea Nitrogen, Respiratory rate, Blood pressure and Age; PaFi ratio of arterial oxygen partial pressure (PaO2) to Fractional Inspired Oxygen (FiO2); SpO2 oxygen saturation; SaFi ratio of SpO2 to FiO2
aResults shown as frequencies and percentages in parenthesis
bResults shown as means and standard deviations in parenthesis